vs
ANI PHARMACEUTICALS INC（ANIP）与BOSTON BEER CO INC（SAM）财务数据对比。点击上方公司名可切换其他公司
BOSTON BEER CO INC的季度营收约是ANI PHARMACEUTICALS INC的1.9倍（$461.6M vs $247.1M），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs -4.1%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs -10.7%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
波士顿啤酒公司是美国知名酿酒企业，1984年由吉姆·科赫与朗达·卡尔曼联合创立。旗下首款产品以美国开国元勋、独立运动先驱塞缪尔·亚当斯命名，后续陆续推出多个自有品牌，2019年正式完成与角鲨头酿酒厂的合并，是北美精酿啤酒行业的核心参与者之一。
ANIP vs SAM — 直观对比
营收规模更大
SAM
是对方的1.9倍
$247.1M
营收增速更快
ANIP
高出33.7%
-4.1%
两年增速更快
ANIP
近两年复合增速
-10.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $461.6M |
| 净利润 | $27.5M | — |
| 毛利率 | — | 46.4% |
| 营业利润率 | 14.1% | 12.4% |
| 净利率 | 11.1% | — |
| 营收同比 | 29.6% | -4.1% |
| 净利润同比 | 367.5% | — |
| 每股收益（稀释后） | $1.14 | $2.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPSAM
| Q1 26 | — | $461.6M | ||
| Q4 25 | $247.1M | $385.7M | ||
| Q3 25 | $227.8M | $537.5M | ||
| Q2 25 | $211.4M | $587.9M | ||
| Q1 25 | $197.1M | $453.9M | ||
| Q4 24 | $190.6M | $402.3M | ||
| Q3 24 | $148.3M | $605.5M | ||
| Q2 24 | $138.0M | $579.1M |
净利润ANIPSAM
| Q1 26 | — | — | ||
| Q4 25 | $27.5M | $-22.5M | ||
| Q3 25 | $26.6M | $46.2M | ||
| Q2 25 | $8.5M | $60.4M | ||
| Q1 25 | $15.7M | $24.4M | ||
| Q4 24 | $-10.3M | $-38.8M | ||
| Q3 24 | $-24.2M | $33.5M | ||
| Q2 24 | $-2.3M | $52.3M |
毛利率ANIPSAM
| Q1 26 | — | 46.4% | ||
| Q4 25 | — | 43.5% | ||
| Q3 25 | — | 50.8% | ||
| Q2 25 | — | 49.8% | ||
| Q1 25 | — | 48.3% | ||
| Q4 24 | — | 39.9% | ||
| Q3 24 | — | 46.3% | ||
| Q2 24 | — | 46.0% |
营业利润率ANIPSAM
| Q1 26 | — | 12.4% | ||
| Q4 25 | 14.1% | -8.6% | ||
| Q3 25 | 15.9% | 11.5% | ||
| Q2 25 | 6.6% | 14.0% | ||
| Q1 25 | 13.3% | 7.4% | ||
| Q4 24 | -2.3% | -13.9% | ||
| Q3 24 | -13.8% | 7.6% | ||
| Q2 24 | 3.7% | 12.2% |
净利率ANIPSAM
| Q1 26 | — | — | ||
| Q4 25 | 11.1% | -5.8% | ||
| Q3 25 | 11.7% | 8.6% | ||
| Q2 25 | 4.0% | 10.3% | ||
| Q1 25 | 8.0% | 5.4% | ||
| Q4 24 | -5.4% | -9.6% | ||
| Q3 24 | -16.3% | 5.5% | ||
| Q2 24 | -1.7% | 9.0% |
每股收益（稀释后）ANIPSAM
| Q1 26 | — | $2.16 | ||
| Q4 25 | $1.14 | $-1.97 | ||
| Q3 25 | $1.13 | $4.25 | ||
| Q2 25 | $0.36 | $5.45 | ||
| Q1 25 | $0.69 | $2.16 | ||
| Q4 24 | $-0.45 | $-3.23 | ||
| Q3 24 | $-1.27 | $2.86 | ||
| Q2 24 | $-0.14 | $4.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $164.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $682.6M |
| 总资产 | $1.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPSAM
| Q1 26 | — | $164.1M | ||
| Q4 25 | $285.6M | $223.4M | ||
| Q3 25 | $262.6M | $250.5M | ||
| Q2 25 | $217.8M | $212.4M | ||
| Q1 25 | $149.8M | $152.5M | ||
| Q4 24 | $144.9M | $211.8M | ||
| Q3 24 | $145.0M | $255.6M | ||
| Q2 24 | $240.1M | $219.3M |
股东权益ANIPSAM
| Q1 26 | — | $682.6M | ||
| Q4 25 | $540.7M | $846.3M | ||
| Q3 25 | $505.8M | $911.0M | ||
| Q2 25 | $436.8M | $912.3M | ||
| Q1 25 | $418.6M | $897.0M | ||
| Q4 24 | $403.7M | $916.2M | ||
| Q3 24 | $405.9M | $1.0B | ||
| Q2 24 | $455.8M | $1.0B |
总资产ANIPSAM
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $920.8M | $1.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPSAM
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $39.9M | ||
| Q3 25 | $44.1M | $101.8M | ||
| Q2 25 | $75.8M | $126.5M | ||
| Q1 25 | $35.0M | $1.9M | ||
| Q4 24 | $15.9M | $41.9M | ||
| Q3 24 | $12.5M | $115.9M | ||
| Q2 24 | $17.4M | $96.0M |
自由现金流ANIPSAM
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $22.1M | ||
| Q3 25 | $38.0M | $89.2M | ||
| Q2 25 | $71.8M | $112.2M | ||
| Q1 25 | $32.5M | $-8.0M | ||
| Q4 24 | $13.5M | $18.4M | ||
| Q3 24 | $7.7M | $99.2M | ||
| Q2 24 | $13.0M | $75.6M |
自由现金流率ANIPSAM
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 5.7% | ||
| Q3 25 | 16.7% | 16.6% | ||
| Q2 25 | 34.0% | 19.1% | ||
| Q1 25 | 16.5% | -1.8% | ||
| Q4 24 | 7.1% | 4.6% | ||
| Q3 24 | 5.2% | 16.4% | ||
| Q2 24 | 9.4% | 13.1% |
资本支出强度ANIPSAM
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 4.6% | ||
| Q3 25 | 2.7% | 2.3% | ||
| Q2 25 | 1.9% | 2.4% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 1.3% | 5.8% | ||
| Q3 24 | 3.2% | 2.8% | ||
| Q2 24 | 3.2% | 3.5% |
现金转化率ANIPSAM
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 2.21× | ||
| Q2 25 | 8.87× | 2.09× | ||
| Q1 25 | 2.23× | 0.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.46× | ||
| Q2 24 | — | 1.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SAM
暂无分部数据
